Lifeline Biotechnologies Inc. announced that management is preparing for a filing with the FDA for the company's First Warning System(TM), a capable process designed to assist in the early detection of breast cancer. Lifeline Biotechnologies has in the past year filed for a patent on the recent technological advancements of the First Warning System(TM), which has achieved the robust capability of identifying and classifying tissue abnormalities of the breast with sensitivities (ability to identify) of 95% to 100% and specificities (verify) of 87% to 90%. Currently, it is a well known fact that mammograms are missing an estimated 20% to 30% of the breast cancers.

Lifeline Biotechnologies, Inc. announced that it has hired Brass Bulls to provide the Company with professional services including public relations, corporate finance, merger acquisition and business consultation to assist in achieving Lifeline’s corporate goals. “We are very pleased and look forward to Brass Bulls assisting us, amongst other services, in our search for a strategic partner. The focus will be on building shareholder value and spreading risk. Meantime, our focus is to bring our First Warning System, a process that is designed to assist in the early detection of breast cancer, to market. Our immediate objective is the preparation and submission of a 510(k) application to the FDA for clearance,” stated Jim Holmes, CEO of Lifeline Biotechnologies. Paul Lovito, President of Brass Bulls, stated, “Lifeline has spent over 20 years developing the First Warning System and is now at the final phase towards going to market. The Company is at a critical point in its corporate finance, marketing and public relations needs. We look forward to assisting the Company in building its shareholder value through increased market exposure, corporate transparency and strategic alliances.”

Lifeline Biotechnologies Inc. announced that it has formed a subsidiary to conduct the business of its First Warning(TM) System designed to assist in the early detection of breast cancer.